Prospective Evaluation of Optical Coherence Tomography Usage in the Screening of Eye Diseases
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Glaucoma
- Sponsor
- Oregon Health and Science University
- Enrollment
- 118
- Locations
- 1
- Primary Endpoint
- OCT screening efficacy for detection of early stage eye diseases in comparison to the current standard of care methods
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The primary goal of the trial is to show that optical coherence tomography (OCT) technology can be used to effectively screen for diseases of the eye including glaucoma, macular diseases and keratoconus. Glaucoma is a disease that causes permanent vision loss and is usually accompanied by increased eye pressure. Macular diseases affect sharp, central vision. Keratoconus is a disease that affects the cornea (clear surface covering the colored part of the eye).
Detailed Description
The identification of many eye diseases would significantly benefit from earlier detection than is available with typical eye exams. Optical coherence tomography (OCT) is an imaging technology that can perform non-contact cross-sectional imaging of tissue structure in real time. It is similar to ultrasound B-mode imaging, except that OCT measures the intensity of reflected light rather than sound waves.
Investigators
David Huang
Michael Chiang, MD, Professor, Provisional, Department of Ophthalmology and Medical Informatics & Clinical Epidemiology
Oregon Health and Science University
Eligibility Criteria
Inclusion Criteria
- •Participant undergoing a screening examination at the Casey Eye Institute Outreach Van.
- •Participants must be between the ages of 18 and 89 years old.
Exclusion Criteria
- •Inability to give informed consent.
- •Inability to maintain stable fixation for OCT imaging
Outcomes
Primary Outcomes
OCT screening efficacy for detection of early stage eye diseases in comparison to the current standard of care methods
Time Frame: 1 year
The primary goal of the trial is to show that OCT technology, specifically the FDA cleared iVue, can be used to effectively screen for glaucoma, macular diseases and keratoconus. The rate of detection of these diseases detected using OCT will be compared to the rate of detection by the physician's exam.